Our Stocks to Watch tomorrow include Samoyed Energy Corp. (OTCBB: SMYD), AmeriResource Technologies, Inc. (OTCBB: ARRT), SigmaTel, Inc. (NASD: SGTL), Smith Investment Company (OTC: SMIC), Natural Health Trends Corp. (NASD: BHIP) and IDM Pharma, Inc. (NASD: IDMI).
Visit http://www.otcpicks.com/ to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
SAMOYED ENERGY CORPORATION (OTCBB: SMYD)
"Up 200.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/SMYD.php
Samoyed Energy Corp., a development stage company, engages in the acquisition, exploration, development, and production of oil and gas properties in Canada. The company owns a 3.33% working interest in an oil and gas drilling prospect in Alberta. It also holds interests in oil and gas production, and exploration properties in Alberta. The company was founded in 2005 and is based in Canmore, Canada.
SMYD News:
February 4 - Samoyed Energy Corp. Enters into Letter of Intent with Advanced Voice Recognition Systems, Inc.
Samoyed Energy Corp. (OTCBB: SMYD) announced the signing of a letter of intent for a business combination with Advanced Voice Recognition Systems, Inc. ("AVRS") and other transactions that, upon completion, would result in the current shareholders of AVRS becoming owners of an aggregate of 140,000,000 shares of SMYD common stock, or approximately 86% of the then outstanding common stock of SMYD.
AVRS has developed a speech recognition system for computerized transcriptions that it believes is unique. AVRS's approach to the objective of speech recognition and conversion to text is a radical departure from ASR (automatic speech recognition) commercial "shrink wrap" type products. The AVRS technologies are referred to as Universal Human Interface Technology (UHITTM). AVRS's UHITTM technologies incorporate patented, patent pending and proprietary algorithms, software, hardware and marketing concepts. The UHITTM technologies are planned to offer broad, practical solutions for multi-user business, military, law enforcement and other network applications. AVRS has studied both the successes and failures of standard ASR and AVRS's UHIT based programs. AVRS intends to initially focus on the medical profession because of the profession's extensive use of dictation and its need for multiple applications of speech recognition technology in the generation of reports, documents and medical bills. AVRS has conducted commercial studies and beta testing with Mayo Clinic Scottsdale, UCSD Medical Center and selected transcription companies and VAR's.
In addition to the stock exchange between SMYD and the AVRS shareholders, the letter of intent also contemplates the transfer of all of SMYD's current oil and gas assets and liabilities to SMYD's largest shareholder in exchange for that shareholder's transfer to SMYD of 22,749,998 shares of SMYD common stock currently owned by it. Shareholders of SMYD will also return to the treasury 4,000,000 shares of SMYD common stock owned by them.
The full text of the letter of intent is attached to the company's 8-K report as filed with the U.S. Securities and Exchange Commission ("SEC"). The letter of intent is an expression of intent only, and is subject to the parties entering into a formal exchange agreement. If the exchange agreement is not signed within 60 days, then the proposed business combination will expire.
AMERIRESOURCE TECHNOLOGIES (OTCBB: ARRT)
"Up 100.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/ARRT.php
AmeriResource Technologies, Inc., through its subsidiaries, operates online auction drop-off locations that enables online sale of goods on eBay. As of March 31, 2007, the company operated 8 drop-off locations, as well as 25 affiliate locations. It also develops self-serve/checkout systems that enable customers of fast-food and take-out restaurants to place their food and beverage orders and pay with cash or a credit/debit card; and provides software design and product development for commercial business users doing business on eBay. The company also provides eBay liquidation services for excess inventory, overstock items, and merchandise that has been returned to the retailer; and conducts sales on eBay for the customers. In addition, it provides voice over Internet protocol (IP) communications solutions and IP communications devices. The company was incorporated in 1989 and is based in Las Vegas, Nevada.
ARRT News:
February 4 - AmeriResource Update: BizAuctions Revenues for January 2008 Increase by 335%
AmeriResource Technologies, Inc. (OTCBB: ARRT), a diversified holding company, announced that January revenues (unaudited) for its subsidiary, BizAuctions, Inc., increased by approximately 335% over revenues for the same period in 2007.
"For the month ending January 31, 2008, revenues (unaudited) have increased to approximately $386,495 from approximately $88,844, an increase of $297,651 or 335% over the corresponding month in 2007. BizAuctions' eBay business model continues to demonstrate strong and steady growth while the Company broadens its operations. Management has made great strides in increasing gross profits while reducing monthly operating expenses and has not realized net profits on a consistent basis," comments Delmar Janovec, CEO of AmeriResource.
"BizAuctions employs two primary business models, whereby it liquidates inventory through eBay on consignment for a lucrative commission; and/or it purchases inventory at a fraction of retail price for the purpose of liquidating it for a profit. BizAuctions consigns, buys inventory, and liquidates through eBay," continues Janovec.
BizAuctions' clients have included some of the Nation's leading retail names at the forefront of their industries. With a long-term strategy to provide eBay liquidation services to Fortune 1000 enterprises, BizAuctions is a clear and lucrative solution for most any business to liquidate excess inventory on eBay.
BizAuctions' operations are designed for maximum capacity to handle most any eBay liquidation project. Whether the client is a Fortune 500 company with 1,000 items or a small business with 100 items, BizAuctions can take on most any project and recover funds from clients' excess inventory.
More information is available at www.BizAuctions.com. Investors and media can receive a free investor kit for BizAuctions, Inc. by contacting Investor Relations at investors@BizAuctions.com or (800) 961-3275. A virtual tour of BizAuctions' facilities and flash video presentation can be viewed at www.bizauctions.com/tour.shtml.
The Company encourages the public to read the above information in conjunction with its year-end 10-KSB for December 31, 2006, and the third Quarter 10-QSB for September 30, 2007. The financial statements can be viewed at www.sec.gov.
SIGMATEL INCORPORATED (NASD: SGTL)
"Up 64.25% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/SGTL.php
SigmaTel, Inc., a fabless semiconductor company, engages in the design, development, and marketing of analog-intensive mixed-signal integrated circuits (ICs) in the United States, Taiwan, China/Hong Kong, and Singapore. It offers system-level solution, including highly-integrated ICs, customizable firmware, software development tools, reference designs, and applications support. The company provides its ICs for various digital multimedia products in the consumer electronics markets, including digital media players, printers, and digital televisions. SigmaTel markets its products to original equipment manufacturers and original device manufacturers through independent sales representatives and distributors. The company was founded in 1993 and is headquartered in Austin, Texas.
SGTL News:
February 4 - SigmaTel Reports Fourth Quarter 2007 Results
SigmaTel, Inc. (NASD: SGTL) announced results for the quarter ended December 31, 2007.
Fourth Quarter Financial Review:
Revenues for the fourth quarter of 2007 were $33.2 million with a GAAP net loss of $4.0 million or $0.11 per share. The non-GAAP adjusted net loss for the fourth quarter of 2007 was $2.0 million or a non-GAAP adjusted net loss of $0.06 per share. GAAP gross margin for the quarter was 42.3 percent and non-GAAP gross margin was 43.3 percent. See the reconciling charges set forth in the reconciliation of GAAP to non-GAAP results provided below.
As of December 31, 2007 SigmaTel had cash, cash equivalents, restricted cash and short-term investments of $71.4 million.
Business Update:
"In 2007, we continued our aggressive cost management and restructured the company," said Phil Pompa, CEO of SigmaTel. "We have achieved new design wins across all the product lines and begun to transition to our PMP solutions, the 3600 and 3700 product families. SigmaTel shipped over 1 million 3700 SoCs to OEM/ODMs worldwide, last year."
Executive Summary:
* 5.0 Software Development Kit for the 3700 product family available for the mass market.
* GPS reference design units showcased at CES 2008.
* Kodak launched the ESP3, based on SigmaTel technology, at CES.
* SGTV5900 adopted by Samsung and shipping in mass production.
"Development has begun on solutions for different consumer markets," said Phil Pompa, CEO of SigmaTel. "New product announcements are expected later on in this quarter with more details available at that time."
First Quarter 2008 Outlook:
For the first quarter of 2008, the company anticipates revenue of $17 million to $22 million with non-GAAP gross margins of approximately 44 percent, plus or minus a couple of points. SigmaTel's gross margin percentage varies primarily with product mix, pricing, and unit costs.
GAAP diluted loss per share is expected to be $0.40 to $0.30 with non-GAAP adjusted net loss per share expected to be $0.35 to $0.25, based on 36.1 million diluted weighted average shares outstanding.
For more information on SigmaTel, visit www.sigmatel.com.
SMITH INVESTMENT COMPANY (OTC: SMIC)
"Up 48.44% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/SMIC.php
Smith Investment is a diversified company with headquarters in Milwaukee, Wisconsin. Its product lines include multicolor printing and related services and commercial warehousing, trucking and packaging. The company also owns a control position in A. O. Smith Corporation (NYSE: AOS).
SMIC News:
February 4 - Smith Investment Company Proposes Restructuring of Holdings in A. O. Smith Corporation
Smith Investment Company (OTC: SMIC) announced that it has made a proposal to restructure its holdings in A. O. Smith Corporation (NYSE: AOS). The proposed transaction would result in the shareholders of Smith Investment having direct ownership of the same number and type of A. O. Smith shares currently held by Smith Investment. Smith Investment's common stock has been valued at a significant discount to the underlying value of the A. O. Smith shares held by Smith Investment. The proposed transaction is intended to allow Smith Investment's shareholders to realize the underlying value of Smith Investment's holdings in A. O. Smith and provide enhanced liquidity to Smith Investment's shareholders.
Pursuant to the proposed transaction, Smith Investment would be merged with a newly formed subsidiary of A. O. Smith. In the merger, Smith Investment's common stock would be exchanged for newly issued shares of A. O. Smith's class A common stock and common stock. It is intended that this exchange would be non-taxable to the shareholders of Smith Investment. Because the total number and type of A. O. Smith shares issued in the proposed transaction would equal the number and type of A. O. Smith shares currently held by Smith Investment, there would be no net change to the number of outstanding A. O. Smith shares. Prior to the merger, Smith Investment intends to distribute in a taxable transaction substantially all of its assets (other than its holdings in A. O. Smith) to the shareholders of Smith Investment. The proposal also contemplates that, prior to the merger, substantially all of Smith Investment's pre-closing liabilities would be discharged or assumed by the entity or entities in which Smith Investment's distributed assets are held.
A special committee comprised of two independent directors from Smith Investment's board of directors recommended the making of the proposal. The Smith Investment special committee was formed to consider possible transactions on behalf of the shareholders of Smith Investment other than certain members of the Smith family and trusts for the benefit of certain members of the Smith family. The Smith Investment special committee has engaged independent financial and legal advisors to assist it in completing its review. Smith Investment's board of directors has agreed that it will not approve any transaction without the prior recommendation of the Smith Investment special committee.
Before recommending the proposal, the Smith Investment special committee consulted with certain Smith Investment shareholders holding in the aggregate a majority of Smith Investment's common stock. These shareholders separately indicated to the Smith Investment special committee that they would support a transaction on substantially the terms proposed. These shareholders also separately indicated to the Smith Investment special committee that they would not support any alternative transaction that resulted in a sale of Smith Investment or otherwise eliminated or limited the dual class voting structure at A. O. Smith.
Smith Investment indicated that the proposal is preliminary, and remains subject to negotiation of definitive documentation and approval of the Smith Investment special committee and board of directors. The proposal also requires the approval of the A. O. Smith board of directors. A. O. Smith has not yet had an opportunity to respond to the proposal. There can be no assurance that the proposed transaction or any other transaction will result from the proposal. Except if required by applicable law, Smith Investment does not intend to comment further on the proposal unless and until a definitive agreement with respect to a proposed transaction has been reached.
NATURAL HEALTH TRENDS (NASD: BHIP)
"Up 38.57% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/BHIP.php
Natural Health Trends Corp., together with its subsidiaries, operates as an international direct selling company. It sells personal care and wellness products under the NHT Global brand primarily to independent distributor networks. Natural Health offers skin care systems that include nonsurgical facelift and spa collection; intimacy enhancing cream for women; intimacy enhancing herbal supplement for men; reconstituted morinda citrifolia fruit juice with various flavors; lip enhancing gloss; dietary supplements; weight management products; lactose-free whey protein powder that provides amino acid substrates to stimulate the body's production of an anti-oxidant and intracellular glutathione peroxidase; cell hydration products; and beverages with a blend of exotic fruits and berries rich in antioxidants and lycopene. It operates in the United States, Canada, Hong Kong, Macau, Taiwan, Singapore, the Philippines, Indonesia, Australia, New Zealand, South Korea, Japan, Mexico, Slovenia, and the People's Republic of China. The company was founded in 1988 and is headquartered in Dallas, Texas.
BHIP News:
February 4 - Natural Health Trends Corp. Celebrated Outstanding Sales Performance and DSA Membership in Taiwan
Natural Health Trends Corp. (NASD: BHIP), an international direct selling company (the "Company"), announced that NHT Global (Taiwan), a wholly owned subsidiary, successfully held an annual recognition ceremony to celebrate outstanding sales performance in year of 2007.
This annual recognition and celebration ceremony was attended by about 600 members on January 12th, 2008. Over 100 members with distinguished sales performance were recognized and given the award of a free ski trip to Korea, which also included a visit to the Company's office in Seoul. In addition, the Company announced that NHT Global (Taiwan) recently became a member of the Direct Selling Association in Taiwan.
Mrs. Wanda Yeh, General Manager, NHT Global Taiwan, said, "We are very proud to announce this great news in such an important event. Becoming a member of DSA Taiwan is certainly a major milestone." She further delivered special thanks to all members for their support to make Taiwan one of the Company's core markets and believed that greater sales performance can be obtained for 2008, which will include an incentive trip to Zhuhai, China.
IDM PHARMACEUTICALS INCORPORATED (NASD: IDMI)
"Up 44.30% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/IDMI.php
IDM Pharma, Inc., a biopharmaceutical company, engages in the development of products to treat and control cancer. The company primarily develops product candidates to destroy residual cancer cells, as well as product candidates to stimulate an immune response and prevent tumor recurrence. Its products include Junovan, an immune system stimulant, which completed phase III study for the treatment of osteosarcoma; Bexidem, a cell-based immunotherapeutic, which is in phase II trials for the treatment of bladder cancer; and Uvidem, which is in Phase II clinical trials for the treatment of melanoma, consists of dendritophages and melanoma tumor cell lysates. The company's products also include EP-2101, which has multiple tumor-associated CTL epitopes, is in Phase II trials for the treatment of non-small cell lung cancer; and Collidem, which is in Phase I/II trails for the treatment of Colorectal cancer, consists of dendritophages and tumor associated antigen peptides. It operates in the United States and France. IDM Pharma has collaboration agreements with sanofi-aventis S.A; Medarex, Inc.; GenPharm International, Inc.; Novartis; and Biotecnol S.A. The company is based in Irvine, California.
IDMI News:
February 4 - IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Children's Oncology Group Report Shows the Addition of L-MTP-PE to Chemotherapy Reduced the Risk of Death by 30% in Osteosarcoma Patients
IDM Pharma, Inc. (NASD: IDMI) announced the Journal of Clinical Oncology (JCO) has published findings from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133), entitled "Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival - A Report from the Children's Oncology Group." The landmark clinical trial, which is the largest study completed in this disease was a National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG).
The COG's findings were based on long-term follow up of 662 patients with newly diagnosed non-metastatic osteosarcoma treated in the Phase 3 trial and demonstrated that the addition of L-MTP-PE to chemotherapy following surgery resulted in statistically superior Overall Survival (OS) the first stated aim of the study.
In the past two decades, there have been no treatment advances for patients with osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
"L-MTP-PE in combination with chemotherapy has demonstrated a significant long-term overall survival advantage in the largest Phase 3 clinical trial completed in patients with osteosarcoma," said Dr. Paul Meyers, vice chair, department of pediatrics at Memorial Sloan-Kettering Cancer Center and principal investigator of the Phase 3 trial. "These results are encouraging for children and young adults with osteosarcoma, considering the lack of progress for these patients in the last 20 years."
The JCO publication highlighting long-term follow up from this study formed the basis of the recent oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), regarding the Marketing Authorization Application (MAA) for L-MTP-PE for the treatment of patients with non-metastatic, resectable osteosarcoma. Updated results from this study were previously presented at the Connective Tissue Oncology Society (CTOS) annual meeting in November 2007. In addition, the new JCO publication highlights the long-term OS data whereas a prior JCO publication in 2005 focused on an Event Free Survival (EFS) additional analysis.
"These findings of statistically superior overall survival in long-term patient follow-up validate the survival benefit offered by L-MTP-PE and underscore the desperate need for new treatments for osteosarcoma patients," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We believe these findings were critical to the recent opinion from the Committee for Medicinal Products for Human Use in Europe and are a positive step toward bringing this important treatment to the European market and potentially gaining approval in the United States."
Study design and findings:
The multicenter, open label, randomized, factorial, four parallel treatment group Phase 3 study was designed to evaluate the effects of patient outcome of the addition of L-MTP-PE to three-drug chemotherapy (cisplatin, doxorubicin, and methotrexate) or four-drug-chemotherapy (cisplatin, doxorubicin, methotrexate, and ifosfamide) in patients with newly diagnosed resectable osteosarcoma without metastatic disease.
Patients received one of four prospectively randomized treatments and all patients received identical cumulative doses of cisplatin, doxorubicin, and methotrexate and underwent definitive surgical resection of primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2x2 factorial design.
In the published analysis, the chemotherapy regimens without L-MTP-PE resulted in similar OS and EFS. Overall Survival after six years of follow-up in patients treated with chemotherapy and L-MTP-PE was 78%, compared to 70% in patients treated only with chemotherapy (p=0.03). The addition of L-MTP-PE to chemotherapy resulted in approximately 30% decrease in the risk of death. EFS, an additional analysis which includes the occurrence of secondary malignancies, after six years of follow-up in patients treated with chemotherapy and L-MTP-PE was 67% compared to 61% in patients treated only with chemotherapy (p=0.08).
Treatment with L-MTP-PE was generally well tolerated in all phases of study. Adverse events were mild to moderate in severity and included chills, fever, nausea, vomiting, myalgia, headache, tachycardia (fast heart rate), hypo- and hypertension, fatigue and shortness of breath, all of which are consistent events with the activation of monocytes and macrophages by L-MTP-PE and the flu-like symptoms that follow cytokine release. These side effects are readily prevented or treated with acetaminophen.
L-MTP-PE Regulatory Status:
The Company recently announced that following presentation of data at an oral explanation hearing before the CHMP, the Committee determined in a non-binding opinion that L-MTPE-PE suggested a possible clinical benefit in terms of survival and granted the Company a clock stop, or time extension. The clock stop will allow the Company additional time to respond to all the remaining questions regarding the MAA.
The CHMP has requested clarification of the existing data in order to gain assurance about the quality of the data before drawing any final conclusions from the data presented. In addition, the Company is required to address a number of remaining questions relating to chemistry, manufacturing and controls (CMC). The Company now expects to receive a final opinion from the CHMP in the third quarter and a final decision from the European Commission in the fourth quarter of 2008.
L-MTP-PE was granted orphan drug status in Europe in 2004. The MAA for L-MTP-PE was submitted to the EMEA and accepted for review in November 2006.
As previously announced, in the United States the Company continues to work with COG as well as external experts and advisors to gather patient follow up data from the Phase 3 clinical trial of L-MTP-PE conducted by COG and to respond to other questions in the not approvable letter the Company received from the U.S. Food and Drug Administration (FDA).
L-MTP-PE was granted orphan drug status in the United States in 2001. The new drug application (NDA) for L-MTP-PE was submitted to FDA in October 2006 and was accepted for review in December 2006.
ABOUT OSTEOSARCOMA
About 3 percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.
Osteosarcoma is an orphan disease with fewer than 1,000 new cases diagnosed in the U.S. each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group, the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
